Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions

Chest

Volumn 136, Issue 1, 2009, Pages 205-211

  Lin, Meng Chih ^a   Chen, Yung Che ^a   Wu, Jiun Ting ^a   Ko, Yang Chin ^a   Wang, Chin Chou ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EMERGENCY WARD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAPNEUMONIC PLEURAL EFFUSION; PLEURA EFFUSION; PLEURA FLUID; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; TUBE;

EID: 67650844444     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1134     Document Type: Article

References (24)

1. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med 1980; 69:507-512
2. Ferguson AD, Prescott RJ, Selkon JB, et al. The clinical course and management of thoracic empyema. Q J Med 1996; 89:285-289
3. Porcel JM, Vives M, Esquerda A, et al. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir Med 2006; 100: 933-937
4. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J 1997; 112:1291-1292
5. Davies CWH, Kearney SE, Gleeson FV, et al. Predictors of outcome and long term survival in patients with pleural infection. Am J Respir Crit Care Med 1999; 160:1682-1687
6. Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journal from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-1525
7. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003; 144: 5578-5584
8. Oberhoffer M, Karzai W, Meier-Hellmann A, et al. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor α and interleukin-6 in patients with sepsis. Crit Care Med 1999; 27:1814-1818
9. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21:939-943
10. Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patient outcome team pneumonia severity index. Chest 2005; 128:2223-2229
11. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7:10
12. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotics use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607
13. Christ-Crain M, Stolz D, Bingisser R, et al. D. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:84-93
14. Gaïni S, Koldkjaer OG, Møller HJ, et al. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Critical Care 2007; 11:R76
15. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 3:1730-1754
16. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829
17. Fine MJ, Auble TE, Yearly DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 23:243-250
18. Davies CWH, Gleeson FV, Davies RJO. BTS guidelines for the management of pleural infection. Thorax 2003; 58(suppl): 18-28
19. Tang BMP, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critical ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217
20. Duflo F, Debon R, Monneret G, et al. Alveolar and serum procalcitonin. Anesthesiology 2002; 96:74-79
21. Sasse SA, Jadus MR, Kukes GD. Pleural fluid transforming growth factor-beta1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003; 168: 700-705
22. Linscheid P, Schaer DJ, Seboek D, et al. Transient expression of procalcitonin and the vasodilating neuropeptide CGRP upon monocyte-adhesion. Crit Care Med 2004; 32:1715-1721
23. Colice GL, Curtis A, Desclauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000; 118:1158-1171
24. Tokuda Y, Matsushima D, Stein GH, et al. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006; 129:783-790